A part of our preclinical trials realised for TOTUM•63, active ingredient of VALEDIA®, our product for type 2 diabetes prevention, has been selected for the next “french speaking society of Diabetes” congress that will take place in Lyon (France), 22-25 march. Those works named: «Valedia®, a new candidate for AMPK regulation and type 2 Diabetes prevention”, show how Valedia® limits T2D development on db/db mice using a cellular mechanism that involve AMPK, a key enzyme of metabolism.